Respiratory muscle strength can improve the prognostic assessment in COPD

Author:

Silva Rebeca Nunes,Goulart Cássia da Luz,de Oliveira Claudio R.,Mendes Renata Gonçalves,Arena Ross,Myers Jonathan,Borghi-Silva Audrey

Abstract

AbstractImpaired lung function, respiratory muscle weakness and exercise intolerance are present in COPD and contribute to poor prognosis. However, the contribution of the combination of these manifestations to define prognosis in COPD is still unknown. This study aimed to define cut-off points for both inspiratory and expiratory muscle strength (MIP and MEP, respectively) for mortality prediction over 42-months in patients with COPD, and to investigate its combination with other noninvasive established prognostic measures (FEV1, O2peak and 6MWD) to improve risk identification. Patients with COPD performed pulmonary function, respiratory muscle strength, six-minute walk and cardiopulmonary exercise tests, and were followed over 42 months to analyze all-cause mortality. A total of 79 patients were included. The sample was mostly (91.1%) comprised of severe (n = 37) and very severe (n = 34) COPD, and 43 (54%) patients died during the follow-up period. Cut-points of ≤ 55 and ≤ 80 cmH2O for MIP and MEP, respectively, were associated with increased risk of death (log-rank p = 0.0001 for both MIP and MEP) in 42 months. Furthermore, MIP and MEP substantially improved the mortality risk assessment when combined with FEV1 (log-ranks p = 0.006 for MIP and p < 0.001 for MEP), O2peak (log-rank: p < 0.001 for both MIP and MEP) and 6MWD (log-ranks: p = 0.005 for MIP; p = 0.015 for MEP). Thus, patients severely affected by COPD presenting MIP ≤ 55 and/or MEP ≤ 80 cmH2O are at increased risk of mortality. Furthermore, MIP and MEP substantially improve the mortality risk assessment when combined with FEV1, V̇O2peak and 6MWD in patients with COPD.

Funder

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Sao Paulo Research Foundation

Publisher

Springer Science and Business Media LLC

Reference37 articles.

1. The global initiative for chronic obstructive lung disease—global strategy for the diagnosis, management, and prevention of COPD—GOLD COPD Report: 2023 update. Lancet Respir. Med. (2022)

2. Almagro, P. et al. Finding the best thresholds of FEV1 and Dyspnea to predict 5-year survival in COPD patients: The COCOMICS study. PLoS ONE 9(2), e89866 (2014).

3. Rodrigues, A. et al. Cluster analysis identifying patients with COPD at high risk of 2-year all-cause mortality. Chron. Respir. Dis. 1(16), 147997231880945 (2019).

4. Ewert, R. et al. Value of cardiopulmonary exercise testing in the prognosis assessment of chronic obstructive pulmonary disease patients: A retrospective. Multicent. Cohort Study. Respir. 101(4), 353–366 (2022).

5. American Thoracic Society. ATS/ERS Statement on respiratory muscle testing. Am. J. Respir. Crit. Care Med. 166, 518–624 (2002).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3